Full-Time

Senior Packaging Engineer 1

Integra LifeSciences

Integra LifeSciences

1,001-5,000 employees

Regenerative medicine, surgical devices provider

Compensation Overview

$81.7k - $112.7k/yr

+ Bonus + Commission + Equity

Columbia, MD, USA

In Person

Bachelor's, Master's, PhD

Category
Mechanical Engineering (1)
Required Skills
GD&T
FDA Regulations
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Integra LifeSciences

See people who can refer or advise you

Requirements
  • Bachelor degree with 8+ years of experience or equivalent education and years of experience
  • Master degree with 5+ years of experience or equivalent education and years of experience
  • Doctoral degree with 3+ years of experience or equivalent education and years of experience
  • Strong knowledge of Quality System Regulation (QSR), GMP, Design Controls, and basic Process Validation principles within the medical device industry, along with familiarity with FDA, ISO, ASTM, and ISTA requirements for packaging and labeling, including the ability to apply relevant standards such as ISO 11607 (Parts 1 and 2), ISO 13485, ISO 14971, and FDA 21 CFR Part 820 using established procedures and guidance
  • Solid understanding of packaging materials, structures, components, and related conversion processes, with opportunity to build knowledge through hands-on experience
  • Ability to read and interpret engineering drawings, with exposure to GD&T methodologies
  • Ability to manage multiple assigned tasks and priorities with direction, adapting to changing project needs
  • Strong working knowledge and application of statistical analysis methods such as DOE, ANOVA, capability analysis, histograms, and normality testing to support engineering decisions
  • Strong technical writing and documentation skills, with the ability to independently develop clear, accurate protocols, reports, and specifications
  • Effective written and verbal communication skills, with the ability to influence cross-functional teams and communicate technical concepts, risks, and recommendations
  • Be fully versed in the use of Microsoft Office software and tools (Outlook, Project, PowerPoint, Word, & Excel) and use of statistical tools
Responsibilities
  • Lead the planning, design, development, and improvement of package systems for sterile and non-sterile medical devices by executing assigned tasks using established requirements and procedures
  • Ensure medical device packaging meets defined requirements for end user functionality, safety, manufacturability, regulatory compliance, sustainability, and business objectives through application and interpretation of applicable standards and processes
  • Define and refine design requirements, performance criteria, and business needs through cross-functional collaboration, leveraging technical expertise and engineering judgment
  • Collaborate with R&D, Quality, Regulatory, Labeling, Operations, and suppliers to drive the design, development, validation, and implementation of package systems across the product lifecycle
  • Lead or contribute significantly to packaging team initiatives focused on best practices, quality improvements, cost effectiveness, and standard work, identifying opportunities for process improvement
  • Apply technical knowledge of packaging materials, processes, and test methods, including design controls, risk management, and validation principles, to support project execution and decision-making
  • Independently execute assigned project tasks with guidance, including documentation, coordination with team members, and execution of defined methodologies, with increasing independence as experience is gained
  • Develop and evaluate packaging concepts using internal and external resources, providing technical direction and recommendations
  • Support process validation activities with a primary focus on packaging-related inputs, including contributing to OQ and PQ execution as needed
  • Analyze data, identify trends and root causes, and develop conclusions and recommendations based on multiple sources of information
  • Prepare and review technical reports, protocols, and documentation summarizing test results, DOE outcomes, and engineering conclusions
  • Provide guidance to junior engineers and may lead small project teams or workstreams, including training and coordination of assigned tasks

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 production started at Braintree, supporting a planned Q4 SurgiMend relaunch.
  • Integra reaffirmed 2026 organic growth guidance of 0.8% to 3.3%.
  • Management targets $200 million operating cash flow as supply reliability improves.

What critics are saying

  • FDA's January 2026 MediHoney recall covered all lots after 11 serious injuries.
  • Quality-system failures still threaten SurgiMend and DuraRepair timelines through 2026.
  • Net debt was $1.6 billion in Q1 2026, limiting strategic flexibility.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, tissue reconstruction, and regenerative wound-care niches.
  • Its Braintree, Massachusetts facility centralizes resumed PriMatrix and SurgiMend manufacturing.
  • Few medtech peers combine biologics, implants, and surgical instruments at this scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.

Yahoo Finance
May 15th, 2026
Integra LifeSciences beats Q1 expectations, raises full-year EPS guidance to $2.45

Integra LifeSciences reported first-quarter results that beat Wall Street expectations, with revenue of $391.9 million and adjusted EPS of $0.54, surpassing estimates by 2.6% and 33.4%, respectively. The medical device company attributed the performance to stronger tissue reconstruction demand, improved supply execution and operational improvements. CEO Stuart Essig emphasised that quality remediation and operational work enabled more reliable product availability. CFO Lea Knight said increased gross margins were driven by favourable product mix, tariff benefits and reduced remediation costs. The company reaffirmed its full-year revenue guidance of $1.68 billion whilst raising adjusted EPS guidance to $2.45, a 4.3% increase. Operating margin improved to 10.4% from 8.2% year-on-year. Management indicated no plans for divestitures, focusing instead on current product mix and gradual market share recovery.

Yahoo Finance
May 5th, 2026
Integra LifeSciences beats Q1 guidance, raises EPS outlook on tariff gains

Integra LifeSciences reported first-quarter results exceeding guidance, with revenue of $392 million and adjusted earnings per share of $0.54. Revenue increased 2.4% on a reported basis and 1.3% organically, driven by product demand and supply improvements. The company announced leadership changes, with Chairman Stuart Essig resuming the role of President and CEO following Mojdeh Poul's departure. Essig said the decision was mutual and cited differences in strategic topics, though transformation initiatives will continue. Mike McBreen was appointed as the company's first Chief Commercial Officer to elevate commercial priorities. Integra raised its full-year adjusted EPS guidance by $0.10, primarily due to favourable tariff outcomes in the first quarter. CFO Lea Knight noted a $0.02 net tariff benefit but said future tariff assumptions remain uncertain.

Associated Press
May 5th, 2026
Integra LifeSciences Q1 revenues rise 2.4% to $391.9M, raises full-year EPS guidance

Integra LifeSciences reported first quarter 2026 revenues of $391.9 million, up 2.4% on a reported basis and 1.3% organically compared to the prior year. The medical technology company posted adjusted earnings per diluted share of $0.54, up from $0.41 in the prior year. The company reaffirmed full-year 2026 revenue guidance of $1.662 billion to $1.702 billion whilst raising its adjusted earnings per share guidance to $2.40 to $2.50, up from the previous range of $2.30 to $2.40. Adjusted EBITDA for the quarter was $76.2 million, representing 19.4% of revenue, compared to $63.6 million or 16.6% in the prior year. The company generated $9.8 million in operating cash flow during the quarter, with net debt standing at $1.6 billion.